

Complications of Therapies

Pulmonary complications of medical treatment

Drug-induced lung disease

Radiation pneumonitis and pulmonary fibrosis

Dr Abu Suraih Sakhri


MBBS, MD (Pathology)

www.abusuraihsakhri.com

Learning objectives

- Recognize the major pulmonary injury patterns linked to therapies.
- Explain how selected drugs and thoracic irradiation produce lung injury.
- Connect exposure history, pathology, clinical effects, and disease evolution.
- Distinguish acute pneumonitis from chronic fibrotic sequelae.

Therapeutic exposure can injure several lung compartments



Two sources of therapy-associated pulmonary injury

Drug-associated

Cytotoxic agents, antiarrhythmics, antimicrobials, ACE inhibitors; Injected particulates

Radiation-associated


Lung damage after irradiation for intrathoracic or adjacent tumors

Therapy complications: Morphology is heterogeneous

Compartment / pattern	Illustrative lesion	Relevant exposure
Interstitial tissue	Pulmonary fibrosis	Bleomycin; nitrofurantoin
Small airways	Bronchiolitis obliterans	Drug-associated pattern (class-level)
Airspaces / interstitium	Eosinophilic pneumonia	Drug-associated pattern (class-level)
Microvasculature	Foreign-particle granulomas	Intravenous drug adulterants


The affected anatomical compartment shapes pathology

Alveolar interstitium




Septum

Small airway



Airway lumen

Microvasculature



Vascular wall

Therapeutic injury is not one histologic diagnosis

- Different drugs may produce different structural patterns of damage.
- One pattern can have several alternative causes.
- A treatment history is therefore essential to interpret nonspecific lung injury.
- Interpret the tissue pattern together with timing and exposure.

Think in terms of injury, repair and sequelae

Initial insult

Therapy-related tissue
injury

Outcome

Resolution or
persistent fibrosis

**Inflammatory
phase**

Pneumonitis or
alveolitis

Clinical interpretation begins with treatment history

- Document the precise drug or radiotherapy exposure.
- Determine whether symptoms started during or after treatment.
- Ask whether injury localizes to the radiation field.
- Avoid assigning causation from exposure alone.

Therapeutic lung disease versus competing processes

Supports therapy-related injury

Temporally plausible exposure; Matching distribution; Compatible lung-injury pattern

Requires separate consideration


Infection, malignancy-related disease, or other interstitial lung disorders

Drug-associated pulmonary pathology: Recognized patterns

- Interstitial fibrosis alters parenchymal compliance and gas exchange.
- Bronchiolitis obliterans narrows or obstructs small airways.
- Eosinophilic pneumonia is an inflammatory airspace / interstitial pattern.
- These manifestations are patterns of injury, not agent-specific signatures.


Three morphologic drug-injury patterns

Interstitial fibrosis




Expanded septal tissue

Bronchiolitis obliterans



Narrowed airway lumen

Eosinophilic pneumonia




Inflammatory airspace
pattern


Bleomycin: A cytotoxic pulmonary exposure

- Bleomycin is used as an antineoplastic cytotoxic drug.
- It as an example of drug-induced pulmonary damage.
- A clinically important sequela is pulmonary fibrosis.
- Pulmonary toxicity is separate from the intended antitumor effect.


Bleomycin injury has direct and inflammatory components




Direct toxicity and alveolar inflammation can coexist



Direct injury



Inflammatory influx



Injury plus scarring

Bleomycin: Interpreting a fibrotic endpoint

- Fibrosis denotes deposition of persistent interstitial connective tissue.
- Progressive remodeling may interfere with alveolar gas exchange.
- A fibrotic lesion alone cannot prove prior bleomycin exposure.
- Correlation with chemotherapy history is required.

Mechanism and outcome are different levels of explanation

Mechanism

Direct cytotoxic injury and inflammatory recruitment explain how damage begins

Morphologic endpoint

Interstitial fibrosis records a potentially persistent tissue response

Case: Dyspnea after cancer chemotherapy

A patient receives a bleomycin-containing cancer regimen.

Respiratory symptoms subsequently arise, with evidence of interstitial lung injury.

Which causal mechanisms are relevant?

What can and cannot be concluded from fibrosis alone?

Case interpretation: Bleomycin-associated injury

Bleomycin is a plausible etiologic exposure in this clinical setting.

Both direct toxicity and inflammatory recruitment.

Fibrosis is compatible with the described injury endpoint.

Temporal association and compatible morphology support—but do not alone establish—causation.


Amiodarone: Pulmonary accumulation matters

- Amiodarone is used to treat cardiac arrhythmias.
- The drug preferentially concentrates in pulmonary tissue.
- The textbook associates this accumulation with significant pneumonitis.
- The clinical lesion differs conceptually from uncomplicated medication-related cough.

Amiodarone: Interpret the quoted frequency carefully

Robbins statement	Interpretation
Significant pneumonitis: 5%–15%	Textbook-reported range in exposed patients
Pulmonary accumulation	Important exposure characteristic
Applicability	Not a personalized risk estimate or universal rate

Amiodarone: Tissue exposure and pneumonitis



Robbins association shown without unsupported pharmacologic mechanism

Amiodarone pneumonitis: Clinicopathologic reasoning

- The therapeutic indication is cardiac arrhythmia.
- A pulmonary complication can develop despite use for a nonpulmonary disease.
- The diagnosis should be considered when compatible lung injury follows exposure.
- Do not treat every new respiratory symptom in a treated patient as drug toxicity.

Bleomycin and amiodarone: Distinguish the emphasis

Bleomycin

Cytotoxic cancer drug; Direct injury plus inflammatory recruitment; Pulmonary fibrosis

Amiodarone

Antiarrhythmic with lung accumulation;
Significant pneumonitis described

Nitrofurantoin: An antimicrobial linked to fibrosis

- Nitrofurantoin is used to treat urinary tract infection.
- Robbins explicitly links this agent to pulmonary fibrosis.
- A nononcologic prescription can therefore be relevant to interstitial lung disease.
- Source does not specify dose, latency or a unique tissue signature.

Different clinical indications, convergent lung findings

Anticancer exposure

Bleomycin: Damage and fibrosis

Antimicrobial exposure

Nitrofurantoin: Associated pulmonary fibrosis

ACE-inhibitor cough: An important distinction

- Angiotensin-converting enzyme inhibitor–induced cough is common.
- Cough alone is a symptom, not evidence of pulmonary fibrosis.
- A cough-predominant adverse effect must not be conflated with interstitial pneumonitis.
- The Robbins paragraph does not specify the mechanism of ACE-inhibitor cough.


A symptom cannot be substituted for a tissue pattern

Clinical or tissue finding	What it establishes
Cough after ACE inhibitor	Recognized treatment-associated symptom
Pneumonitis after amiodarone	Potential parenchymal inflammatory injury
Fibrosis after bleomycin	Potential chronic structural tissue response

Intravenous drug use: Infectious injury predominates


- The most frequent pulmonary complications are infections.
- This pathway is distinct from direct pharmaceutical toxicity.
- A patient may also develop noninfectious injury from injected particulate material.
- Both mechanisms must be recognized when interpreting lung pathology.

Injected insoluble particles can lodge in small lung vessels



Foreign-particle lung disease centers on the microvasculature

Vessel wall



**Particulate retention →
granulomatous response**

Schematic site of injury; Not polarized-light or H&E histology

Why particulate deposits provoke granulomatous change

- Particulate material lodges in the pulmonary microvascular bed.
- The tissue response may include granulomatous inflammation.
- Fibrosis may accumulate around the resulting chronic lesions.
- This distribution should prompt a search for an intravascular exposure history.

Injection-related pulmonary complications: Two pathways

Infectious

Infection is the most frequent pulmonary complication

Noninfectious

Microvascular particulates may provoke granulomas and fibrosis

Case: Particulate-associated lung granulomas

A lung specimen shows a granulomatous response around small vascular structures.

The clinical history includes intravenous administration of adulterated substances.

Which exposure pathway accounts for the distribution?

What other common pulmonary complication must be considered?

Case interpretation: Vascular particulate injury

Injected particles can travel to and lodge within pulmonary microvasculature.

The resulting tissue response may be granulomatous and fibrotic.

The vascular distribution supports this exposure hypothesis.

Infection remains a major competing or coexisting pulmonary problem.


Drug-related patterns: Do not overassign specificity

Exposure	Textbook-supported association
Bleomycin	Damage via direct and inflammatory mechanisms; fibrosis
Amiodarone	Pulmonary concentration; significant pneumonitis
Nitrofurantoin	Pulmonary fibrosis
ACE inhibitors	Cough
Injected particulates	Microvascular granulomas and fibrosis

Radiotherapy can injure lung near the tumor

- Thoracic radiotherapy is used for tumors of lung, esophagus, breast and mediastinum.
- Radiation pneumonitis is a recognized complication.
- Injury most commonly involves lung within the irradiated field.
- Acute and chronic pulmonary forms are described.

Irradiation field predicts the distribution of injury



Stylized projection field only; Patient-specific beam geometry varies

Acute and chronic radiation lung disease


Acute radiation pneumonitis

Inflammatory / alveolar injury after therapy, with possible systemic symptoms

Chronic radiation injury

Pulmonary fibrosis; May follow acute illness or appear without recognized acute pneumonitis

Radiation injury has a clinically important time course



Timing: Acute radiation pneumonitis

- The acute clinical syndrome at 1–6 months after irradiation.
- Latency should be considered alongside the radiation field.
- Symptoms outside this temporal framework need broader interpretation.
- Latency alone is insufficient to diagnose radiation pneumonitis.

Radiation pneumonitis frequency varies widely

Parameter in Robbins	Reported detail
Acute pneumonitis frequency	3%–44% of patients
Important modifiers stated	Radiation dose and patient age
Interpretation	Broad reported range; not a single universal event rate

Acute radiation pneumonitis: Symptoms

- Fever may accompany the inflammatory lung process.
- Dyspnea can be marked, even relative to irradiated lung volume.
- Pleural effusion is a recognized accompanying manifestation.
- Pulmonary infiltrates may be present on imaging.

Clinical and imaging clues are complementary

Clinical presentation

Fever and disproportionate dyspnea after thoracic irradiation


Anatomic evidence

Pulmonary infiltrates and sometimes pleural effusion; Relation to treatment field


Dyspnea may exceed the visible field volume

- The reported acute syndrome may cause severe respiratory symptoms.
- Symptom intensity need not match the small apparent irradiated volume.
- Severity must not be dismissed solely because the geometric field is limited.
- Clinical and radiologic findings require integrated assessment.


Diffuse alveolar damage is the acute injury pattern



Airspace edema



Hyaline membrane




Epithelial damage


Radiation injury shows reactive epithelial atypia

- Hyperplastic type II pneumocytes may show nuclear atypia.
- These changes occur in an injured and regenerating alveolar epithelium.
- Radiation-associated epithelial atypia must be interpreted in exposure context.
- Cytologic atypia is not by itself proof of a neoplasm.


Injury-related atypia is part of the radiation pattern



Baseline epithelial cell



Reactive type II cell



Atypical fibroblast


Cell outlines purely illustrative; Not histologic diagnostic criteria or morphology at scale

Reactive fibroblasts may also appear atypical

- Atypia of fibroblasts alongside type II pneumocytes.
- The stromal compartment can therefore show treatment-related changes.
- The finding is interpreted alongside alveolar damage and treatment history.
- No stand-alone microscopic criterion is specified in the supplied paragraph.

Foam cells in vessel walls: A vascular clue

Vessel wall



**Foam cells within vessel
wall**

Schematic site of injury; Not polarized-light or H&E histology


Characteristic vascular finding after irradiation

- Foam cells may appear within pulmonary vessel walls.
- The source describes this as characteristic of radiation injury.
- Epithelial atypia may accompany the vascular finding.
- Assess these findings as a constellation rather than isolated pathognomonic signs.

Morphologic constellation in acute radiation injury

Tissue component	Change described by Robbins
Alveoli	Diffuse alveolar damage
Type II pneumocytes	Hyperplasia and atypia
Stroma	Atypical fibroblasts
Vascular walls	Foam cells

Steroid-treated acute illness has two possible courses



Corticosteroid treatment may be followed by recovery; Fibrosis may also arise without a recognized acute episode.

Two outcomes after radiation pneumonitis

Potentially reversible

Symptoms may resolve completely with steroid therapy


Potentially persistent

Other cases progress to chronic pneumonitis and fibrosis


Chronic fibrosis may appear without overt acute illness

- Chronic radiation pneumonitis represents a fibrosing pulmonary outcome.
- An antecedent clinically apparent acute episode is not mandatory.
- Absence of recorded acute pneumonitis does not exclude later fibrosis.
- Review the irradiation history when interpreting chronic regional scarring.


From alveolar injury to fixed interstitial fibrosis



Injured alveolus




Chronic injury



Fibrotic septum

Advanced radiation fibrosis can burden the right heart



Severe chronic radiation injury: Clinical consequences

- Progressive pulmonary fibrosis can impair respiratory function.
- Cyanosis may appear in the most severe disease.
- Pulmonary hypertension may develop.
- Cor pulmonale represents an important terminal cardiopulmonary complication.

Drug toxicity and radiation injury: Contrasting clues

Dimension	Drug-associated	Radiation-associated
Exposure clue	Drug name and treatment history	Thoracic irradiation and field
Distribution	Varies by agent / process	Often within radiation field
Important examples	Fibrosis, pneumonitis, cough, vascular granulomas	Acute pneumonitis, later fibrosis
Microscopic clues	Agent- and pattern-dependent	DAD plus atypia and vascular foam cells

Case: Delayed dyspnea after breast irradiation

Several months after thoracic irradiation for a breast malignancy, a patient develops fever and dyspnea.

Chest imaging demonstrates a pulmonary infiltrate close to the treatment region.

Which acute complication is plausible?

Which tissue changes would support the suspected injury?

Case interpretation: Acute radiation pneumonitis

Thoracic irradiation and a compatible delay support the exposure link.

Fever, dyspnea and infiltrates align with the textbook syndrome.

Diffuse alveolar damage, type II-cell/fibroblast atypia and vascular foam cells are described morphologic clues.

The case still requires consideration of alternative causes of new infiltrates.

Case: Pulmonary fibrosis without a recognized acute phase

A patient previously received mediastinal irradiation.

Chronic pulmonary scarring develops without documented acute pneumonitis.

Does the missing acute episode refute radiation-associated fibrosis?

What severe cardiopulmonary sequelae could follow progression?

Case interpretation: Chronic radiation injury

No: Chronic fibrosis may occur without an overt preceding acute syndrome.

Progressive disease can cause cyanosis and pulmonary hypertension.

Severe pulmonary vascular loading can lead to cor pulmonale.

Interpret the fibrosis in relation to the irradiated anatomy and other causes.

Avoid five common interpretation errors

- Do not confuse a symptom (cough) with a histologic pattern (fibrosis).
- Do not treat a broad published frequency range as an individual risk.
- Do not assume any atypical irradiated cell is malignant.
- Do not require a documented acute episode before considering chronic radiation fibrosis.
- Do not label a nonspecific injury pattern without an exposure history.

A practical clinicopathologic reasoning sequence



High-yield associations for rapid recall

Therapy / exposure	Core association
Bleomycin	Direct plus inflammatory injury → pulmonary fibrosis
Amiodarone	Lung concentration → pneumonitis
Nitrofurantoin	Pulmonary fibrosis
ACE inhibitors	Common cough
Intravenous particulates	Microvascular granulomas / fibrosis
Thoracic radiation	Acute pneumonitis or chronic fibrosis

Synthesis: Three principles to retain

- Therapy-related pulmonary disease spans multiple tissue compartments.
- The medication or radiation history provides etiologic context, not a stand-alone diagnosis.
- Acute inflammatory damage may resolve or evolve to lasting fibrosis.
- Severe chronic fibrosis can culminate in pulmonary hypertension and cor pulmonale.

Principal references and scope

- Robbins, Cotran & Kumar: Pathologic Basis of Disease, 11th edition (2026), Chapter 15, “Complications of Therapies.”
- Related Chapter 15 sections: diffuse alveolar damage, airway injury, and interstitial disease provide explanatory context.
- Mechanism schematics and hypothetical cases are original instructional interpretations of the textbook.
- No textbook photomicrographs or third-party clinical images have been reproduced.